prime
activ
cell
respons
crucial
achiev
antivir
antitumor
immun
live
attenu
measl
vaccin
strain
use
success
immun
decad
current
investig
trial
oncolyt
virotherapi
avail
revers
genet
system
allow
insert
addit
gene
includ
heterolog
antigen
design
recombin
measl
vaccin
vector
prime
activ
antigenspecif
cell
proofofconcept
use
cytotox
lymphocyt
ctl
line
specif
melanomaassoci
differenti
antigen
tyrosinaserel
model
antigen
chicken
ovalbumin
ova
respect
gener
recombin
measl
vaccin
vector
ova
epitop
cassett
variant
express
fulllength
antigen
respect
immunodomin
epitop
addit
variant
mediat
secret
proteasom
degrad
epitop
show
recombin
measl
viru
vector
mediat
vari
level
mhc
class
mhci
restrict
epitop
present
lead
activ
cognat
ctl
indic
secret
interferongamma
vitro
importantli
recombin
ova
vaccin
also
mediat
prime
oti
cell
dendrit
cell
vaccin
variant
prime
activ
cognat
cell
releas
enhanc
use
secret
epitop
variant
variant
epitop
string
target
proteasom
principl
present
studi
facilit
design
recombin
vaccin
elicit
respons
pathogen
tumor
antigen
liveattenu
measl
vaccin
highli
effect
provid
least
protect
clinic
measl
vaccin
safe
elicit
b
cell
respons
revers
genet
system
avail
allow
insert
foreign
gene
measl
viru
genom
gener
recombin
vaccin
follow
approach
measl
viru
use
vector
platform
gener
vaccin
multipl
pathogen
includ
dengu
viru
hiv
hepat
b
viru
sar
mer
coronavirus
well
malaria
parasit
phase
clinic
trial
measl
vaccin
encod
hiv
env
complet
clinicaltrialsgov
schwarz
vaccin
strain
express
chikungunya
viru
chikv
structur
protein
success
complet
phase
ii
safeti
immunogen
demonstr
patient
achiev
seroconvers
vaccin
mediat
express
chikv
viruslik
particl
use
similar
approach
measlesbas
lassa
viru
vaccin
develop
shown
protect
cynomolgu
monkey
lassa
viru
challeng
measl
vaccin
platform
also
use
tumor
vaccin
measl
vaccin
oncolyt
ie
preferenti
replic
malign
cell
compar
normal
cell
eventu
result
select
tumor
cell
lysi
releas
tumor
antigen
concert
damp
dangerassoci
molecular
pattern
pamp
pathogenassoci
molecular
pattern
viral
infect
oncolyt
virotherapi
act
antigenagnost
situ
tumor
vaccin
herp
viru
talimogen
laherparepvec
approv
fda
ema
sever
oncolyt
virus
current
clinic
trial
includ
vaccinia
adeno
rhabdoand
reovirus
oncolyt
measl
vaccin
clinic
investig
treatment
sever
tumor
entiti
earli
trial
indic
safeti
efficaci
approach
advantag
oncolyt
measl
vaccin
includ
well
document
safeti
record
genom
stabil
versatil
revers
genet
system
insert
immunomodulatori
gene
encod
cytokin
chemokin
immun
checkpoint
antibodi
oncolyt
vector
enhanc
antitumor
immun
anoth
approach
direct
immun
respons
tumor
oncolyt
virus
encod
tumor
antigen
develop
differ
antigen
express
strategi
realiz
recombin
viral
vector
tumor
vaccin
kottk
et
al
pulido
et
al
studi
oncolyt
vesicular
stomat
viru
vsv
cdna
librari
melanoma
prostat
cancer
sever
studi
investig
oncolyt
maraba
virus
encod
fulllength
differenti
cancer
testi
antigen
treatment
hpvassoci
cancer
atherton
et
al
gener
vector
encod
fulllength
hpv
separ
linker
sequenc
mediat
proteasom
degrad
colleagu
design
recombin
measl
vaccin
encod
fulllength
claudin
tumor
antigen
either
alon
combin
murin
leukemia
viru
mlv
gag
latter
strategi
enabl
incorpor
antigen
mlv
viruslik
particl
vlp
increas
immunogen
retrovirus
also
employ
success
ectop
express
antigen
cell
epitop
cytotox
lymphocyt
ctl
respons
essenti
effici
antivir
antitumor
immun
therefor
induct
robust
ctl
respons
integr
success
vaccin
viral
infect
malign
diseas
studi
develop
recombin
measl
schwarz
vaccin
vector
cell
activ
design
epitop
cassett
variant
increas
mhci
epitop
present
test
abil
activ
ctl
use
ovalbumin
ova
tyrosinaserel
synonym
ldopachrom
tautomeras
model
antigen
demonstr
activ
cognat
ctl
recombin
measl
vaccin
vector
vero
cell
african
green
monkey
kidney
epitheli
cell
atcc
obtain
american
type
cultur
collect
atcc
manassa
va
usa
cell
gift
r
cattaneo
mayo
clinic
rochest
mn
usa
cell
immort
mous
dendrit
cell
line
obtain
h
weyd
german
cancer
research
center
heidelberg
germani
cell
gener
lentivir
transduct
describ
previous
ovalbuminspecif
cytotox
cell
ctl
line
recogn
b
restrict
epitop
siinfekl
ctl
line
recogn
epitop
svydffvwl
describ
previous
oti
mice
tcratcrb
bred
center
preclin
research
german
cancer
research
center
accord
institut
guidelin
german
anim
protect
law
obtain
oti
cell
spleen
harvest
untreat
oti
mice
singlecel
suspens
prepar
use
mesh
erythrocyt
lyze
use
ack
buffer
lonza
basel
switzerland
cell
isol
use
pan
cell
isol
kit
ii
mous
miltenyi
biotech
bergisch
gladbach
germani
accord
manufactur
protocol
vero
cell
cultiv
dmem
fc
cell
cultiv
rpmi
fc
cell
cultiv
rpmi
fc
hepe
ctl
line
maintain
sigma
taufkirchen
germani
supplement
fc
mm
lglutamin
uml
penicillin
streptomycin
restimul
describ
previous
brief
vv
supernat
concanavalin
stimul
rat
spleen
cell
cultur
mm
sigma
ad
medium
second
restimul
onward
irradi
gy
syngen
splenocyt
feeder
cell
well
irradi
gy
cell
express
chicken
ovalbumin
express
human
tyrosinaserel
respect
use
restimul
recombin
measl
virus
mev
schwarz
vaccin
strain
mevac
gener
use
revers
genet
system
origin
describ
radeck
et
al
modif
describ
previous
mevac
encod
enhanc
green
fluoresc
protein
egfp
describ
previous
obtain
cdna
ovalbumin
open
read
frame
orf
total
rna
extract
cell
use
rneasi
mini
kit
qiagen
hilden
germani
cdna
synthesi
perform
use
maxima
h
minu
first
strand
cdna
synthesi
kit
thermofish
dreieich
germani
orf
amplifi
pcr
use
follow
primer
includ
restrict
site
underlin
kozak
sequenc
forward
primer
start
stop
codon
bold
print
well
second
stop
codon
case
ovalbumin
compli
rule
six
ggova
mlui
tttacgcgtgccaccatgggctccatcggcg
ggova
asci
rev
tttggcgcgcctattaaggggaaacacatctgcca
mlui
tttacgcgtgccaccatgggccttgtggga
asci
rev
tttggcgcgcctaggcttcctccgtgt
ovalbumin
orf
insert
recombin
mev
harbor
addit
transcript
unit
downstream
mev
h
gene
yield
pcmevac
ova
pcmevac
gener
mev
encod
epitop
cassett
variant
mevac
ova
mevac
synthet
oligonucleotid
design
obtain
eurofin
ebersberg
germani
oligonucleotid
includ
flank
mlui
paui
restrict
site
kozak
sequenc
well
start
stop
codon
design
compli
rule
six
oligonucleotid
clone
mev
harbor
addit
transcript
unit
upstream
mev
n
gene
pcmevac
ubaay
svydffvwlaay
sequenc
encod
peptid
string
obtain
gene
synthesi
eurofin
clone
xbai
sali
site
nub
aay
plasmid
subsequ
pcr
perform
primer
nub
fw
tttacgcgtgccaccatgcagatttttgtgaag
nub
rev
ttttttgcgcgctcattagtcgacataggctgccaa
nub
ova
rev
ttttttgcgcgctcattagtcgacataggctgccaa
sequenc
oligonucleotid
present
supplementari
tabl
rescu
propag
recombin
virus
perform
describ
previous
brief
vero
cell
seed
plate
dmem
fc
kanamycin
transfect
respect
pcmevac
antigenom
plasmid
ng
pcdimer
n
ng
pdimer
l
ng
pcdimer
p
use
fugen
hd
transfect
reagent
promega
madison
wi
usa
syncytia
form
cell
harvest
scrape
propag
vero
cell
viru
passag
perform
multipl
infect
moi
titer
determin
serial
dilut
titrat
assay
calcul
cell
infecti
unit
per
millilit
ciuml
character
viral
replic
kinet
cell
seed
plate
cell
per
well
infect
design
virus
moi
triplic
gener
onestep
growth
curv
cell
scrape
media
triplic
sampl
pool
frozen
liquid
nitrogen
titrat
serial
dilut
titrat
assay
cell
seed
plate
infect
moi
h
cell
lysat
prepar
ripa
buffer
protein
concentr
determin
bca
assay
novagen
madison
wi
usa
equal
amount
protein
load
sdspage
immunodetect
perform
rabbit
polyclon
dct
antibodi
nterminu
abcepta
san
diego
ca
usa
dilut
secondari
goat
antirabbit
igghrp
conjug
bethyl
montgomeri
tx
usa
dilut
melanosom
purifi
melanoma
cell
ultracentrifug
serv
posit
control
monoclon
mous
antiovalbumin
santa
cruz
biotechnolog
dalla
tx
usa
dilut
secondari
rabbit
antimous
igghrp
conjug
bethyl
dilut
use
immunodetect
ovalbumin
chicken
egg
white
serv
posit
control
clone
sigma
dilut
use
load
control
ova
siinfekl
svydffvwl
peptid
synthes
fmoc
chemistri
fulli
autom
multipl
synthes
syro
ii
multisyn
tech
witten
germani
synthesi
carri
preload
wangresin
coupl
agent
hexafluorophosph
hbtu
use
materi
purifi
prepar
hplc
kromasil
revers
phase
column
mm
use
eluent
trifluoroacet
acid
water
acetonitril
water
b
peptid
elut
success
linear
gradient
b
b
min
flow
rate
mlmin
fraction
correspond
purifi
protein
lyophil
purifi
materi
character
analyt
hplc
ms
thermo
finnigan
lcq
thermo
fisher
scientif
waltham
usa
elispot
assay
perform
describ
previous
multiscreen
ha
plate
millipor
burlington
coat
captur
antibodi
antimous
clone
bd
pharmingen
heidelberg
germani
overnight
c
cell
seed
plate
cell
per
well
infect
moi
twentyfour
hour
infect
cell
trypsin
use
target
cell
cell
per
well
ctl
block
plate
serial
twofold
dilut
ctl
begin
cell
per
well
perform
ctl
cocultur
triplic
target
cell
posit
control
consist
synthet
peptid
ng
per
well
uninfect
cell
cell
per
well
concanavalin
sigma
per
well
h
cell
remov
secondari
antibodi
biotinyl
antimous
antibodi
per
well
clone
bd
pharmingen
ad
h
c
follow
incub
streptavidin
alkalin
phosphatas
conjug
bd
pharmingen
dilut
pb
room
temperatur
bcipnbt
substrat
sigmaaldrich
ad
reaction
stop
water
spot
count
use
ctl
elispot
reader
ctl
europ
bonn
germani
elispot
assay
dc
cell
inocul
mevac
variant
moi
h
dc
trypsin
cocultur
establish
either
ctl
oti
cell
well
ctl
isol
oti
cell
cocultur
cell
inocul
mevac
variant
elispot
assay
perform
describ
uv
inactiv
virus
viru
suspens
ciu
ml
optimem
irradi
jcm
uvc
light
uv
stratalink
stratagen
la
jolla
ca
usa
viru
inactiv
confirm
titrat
assay
isotyp
control
biolegend
serv
isotyp
control
detect
infect
cell
antimeasl
viru
f
monoclon
antibodi
specif
measl
viru
fusion
protein
obtain
gerlier
inserm
ecol
normal
de
lyon
lyon
franc
use
dilut
describ
mous
f
ab
igg
hl
apc
conjug
r
system
minneapoli
mn
usa
dilut
second
step
reagent
sampl
acquir
lsr
ii
flow
cytomet
facscanto
ii
flow
cytomet
bd
bioscienc
heidelberg
germani
data
analyz
flowjo
softwar
version
tree
star
inc
ashland
usa
test
extern
load
cell
cell
cultur
supernat
pass
low
protein
bind
filter
merck
darmstadt
germani
test
extern
load
cell
cell
cell
per
well
plate
infect
moi
indic
mevac
variant
tumor
cell
cultur
supernat
harvest
h
postinfect
subject
one
freezethaw
cycl
liquid
nitrogen
transfer
onto
cell
cell
per
well
plate
incub
h
c
flow
cytometri
perform
describ
graph
pad
prism
softwar
version
graphpad
softwar
lajolla
ca
usa
use
data
analys
visual
gener
measl
vaccin
vector
cell
activ
initi
encod
fulllength
murin
melanomaassoci
differenti
antigen
model
antigen
ovalbumin
within
measl
schwarz
vaccin
vector
obtain
mevac
mevac
ova
respect
figur
figur
test
whether
mevac
ova
mevac
activ
cognat
cell
cocultur
infect
target
cell
ctl
line
recogn
b
restrict
epitop
ova
siinfekl
svydffvwl
respect
target
cell
employ
cell
cell
transduc
express
mevac
receptor
infect
measl
vaccin
strain
supplementari
figur
elispot
assay
reveal
releas
cocultur
cell
infect
mevac
encod
respect
antigen
unmodifi
mevac
figur
flow
cytometri
antibodi
specif
siinfekl
bound
b
molecul
confirm
present
ctl
epitop
infect
cell
figur
use
prestimul
ctl
line
level
present
suffici
elicit
strong
ctl
activ
shown
figur
howev
set
cell
surfac
express
epitopepres
mhci
molecul
may
limit
factor
effect
ctl
respons
therefor
design
recombin
measl
vaccin
vector
differ
epitop
cassett
variant
enhanc
mhcirestrict
epitop
present
instead
encod
fulllength
antigen
insert
variant
encod
flow
cytometri
antibodi
specif
siinfekl
bound
b
molecul
confirm
present
ctl
epitop
infect
cell
figur
use
prestimul
ctl
line
level
present
suffici
elicit
strong
ctl
activ
shown
figur
howev
set
cell
surfac
express
epitopepres
mhci
molecul
may
limit
factor
effect
ctl
respons
therefor
design
recombin
measl
vaccin
vector
differ
epitop
cassett
variant
enhanc
mhcirestrict
epitop
present
instead
encod
fulllength
antigen
insert
variant
encod
immunodomin
epitop
enabl
insert
addit
transcript
unit
upstream
mevac
n
gene
figur
accord
transcript
gradient
within
measl
viru
genom
posit
mediat
higher
express
level
virus
upstream
mevac
n
gene
figur
accord
transcript
gradient
within
measl
viru
genom
posit
mediat
higher
express
level
epitop
cassett
variant
includ
epitop
mevac
svydffvwl
mevac
siinfekl
epitop
preced
mous
immunoglobulin
kappa
light
chain
leader
sequenc
secret
signal
mevac
svydffvwl
mevac
siinfekl
well
epitop
string
ntermin
ubiquitin
flank
proteasom
cleavag
site
latter
cassett
conceptu
base
previou
epitop
vaccin
target
proteasom
investig
epitop
flank
residu
variant
five
svdffvwl
one
two
six
siinfekl
epitop
copi
gener
figur
mevac
variant
character
term
replic
kinet
vero
cell
supplementari
figur
figur
indic
asid
infect
addit
factor
contribut
efficaci
epitop
present
differ
mevac
variant
elispot
assay
confirm
activ
svydffvwland
siinfeklspecif
ctl
cell
infect
epitop
cassett
variant
test
figur
consist
signific
differ
spot
number
variant
across
three
independ
experi
indic
epitop
present
limit
factor
set
howev
trend
increas
releas
epitop
string
target
proteasom
figur
case
ova
epitop
cassett
variant
elicit
higher
mean
spot
number
compar
full
length
antigen
figur
despit
slight
dosedepend
effect
observ
variant
one
two
six
epitop
copi
figur
signific
differ
variant
contain
cassett
secret
signal
one
sever
epitop
copi
respect
figur
c
subsequ
experi
focu
ova
antigen
respect
cell
line
reagent
readili
avail
test
whether
extern
load
b
molecul
peptid
releas
infect
cell
contribut
present
siinfekl
cell
lysat
supernat
infect
cell
collect
clear
centrifug
pass
low
protein
bind
filter
exclud
viral
particl
cell
treat
lysat
supernat
stain
neg
b
siinfekl
flow
cytometri
data
shown
indic
set
extern
peptid
load
contribut
mevacmedi
epitop
present
ctl
activ
sinc
dendrit
cell
dc
key
ctl
prime
activ
assess
mevac
variant
cocultur
dc
ctl
contrast
murin
dc
line
show
limit
suscept
mevac
supplementari
figur
cell
expos
mevac
encod
siinfekl
variant
show
low
percentag
posit
b
siinfekl
figur
percentag
b
siinfekl
posit
cell
directli
correl
mev
f
stain
indic
infect
main
determin
epitop
present
wonder
whether
extern
figur
load
dc
lysat
cell
puls
siinfekl
peptid
mediat
epitop
present
dc
either
supplementari
figur
bottom
row
left
panel
test
whether
mevacexpos
dc
activ
siinfeklspecif
ctl
set
cocultur
perform
elispot
assay
despit
overal
low
level
infect
epitop
present
supplementari
figur
figur
observ
signific
secret
cocultur
dc
expos
mevac
encod
fulllength
ovalbumin
contrast
unmodifi
mevac
figur
dc
expos
mevac
encod
epitop
cassett
variant
mediat
even
stronger
ctl
activ
indic
increas
secret
figur
variant
encod
secret
epitop
multipl
proteasometarget
epitop
copi
elicit
highest
level
releas
flow
cytometri
reveal
increas
b
siinfekl
express
cell
infect
mevac
encod
epitop
variant
compar
mevac
ova
figur
supplementari
figur
mevac
siinfekl
elicit
approxim
b
siinfekl
posit
cell
mevac
siinfekl
elicit
approxim
posit
cell
variant
encod
epitop
string
target
proteasom
show
increas
epitop
present
correl
number
siinfekl
repeat
thu
mevac
variant
encod
string
six
epitop
yield
posit
cell
overal
direct
correl
percentag
b
siinfekl
posit
cell
percentag
mev
f
cell
compar
supplementari
figur
indic
asid
infect
addit
factor
contribut
efficaci
epitop
present
differ
mevac
variant
elispot
assay
confirm
activ
svydffvwland
siinfeklspecif
ctl
cell
infect
epitop
cassett
variant
test
figur
consist
signific
differ
spot
number
variant
across
three
independ
experi
indic
epitop
present
limit
factor
set
howev
trend
increas
releas
epitop
string
target
proteasom
figur
case
ova
epitop
cassett
variant
elicit
higher
mean
spot
number
compar
full
length
antigen
figur
despit
slight
dosedepend
effect
observ
variant
one
two
six
epitop
copi
figur
signific
differ
variant
contain
cassett
secret
signal
one
sever
epitop
copi
respect
figur
c
test
whether
peptid
present
viru
suspens
contribut
antigen
present
perform
flow
cytometri
b
siinfekl
elispot
assay
uvinactiv
virus
uvinactiv
virus
elicit
neither
siinfekl
present
secret
siinfeklspecif
ctl
figur
suggest
de
novo
peptid
express
product
infect
cell
requir
ctl
activ
prime
cell
crucial
function
dc
establish
antivir
antitumor
immun
assess
cell
prime
cocultur
dc
expos
mevac
oti
cell
perform
elispot
assay
figur
despit
low
level
infect
b
siinfekl
posit
cell
dc
expos
mevac
encod
fulllength
ovalbumin
siinfekl
epitop
cassett
variant
abl
prime
oti
cell
mevac
encod
secret
epitop
variant
elicit
higher
level
secret
compar
mevac
encod
siinfekl
without
secret
signal
seem
correl
number
epitop
string
releas
exposur
siinfekl
peptid
alon
insuffici
cell
prime
mock
treat
dc
puls
siinfekl
peptid
induc
express
oti
cell
interestingli
dc
expos
mevac
subsequ
puls
siinfekl
elicit
higher
level
secret
result
show
mevac
encod
cell
epitop
mediat
prime
cell
profession
antigen
present
cell
may
promot
dc
function
prime
cell
crucial
function
dc
establish
antivir
antitumor
immun
assess
cell
prime
cocultur
dc
expos
mevac
oti
cell
perform
elispot
assay
figur
despit
low
level
infect
b
siinfekl
posit
cell
dc
expos
mevac
encod
fulllength
ovalbumin
siinfekl
epitop
cassett
variant
abl
prime
oti
cell
mevac
encod
secret
epitop
variant
elicit
higher
level
secret
compar
mevac
encod
siinfekl
without
secret
signal
seem
correl
number
epitop
string
releas
exposur
siinfekl
peptid
alon
insuffici
cell
prime
mock
treat
dc
puls
siinfekl
peptid
induc
express
oti
cell
interestingli
dc
expos
mevac
subsequ
puls
siinfekl
elicit
higher
level
secret
result
show
mevac
encod
cell
epitop
mediat
prime
cell
profession
antigen
present
cell
may
promot
dc
function
cytotox
cell
respons
essenti
robust
antivir
antitumor
immun
strategi
induc
ctl
respons
vaccin
includ
peptid
dna
vaccin
target
dc
immun
viral
vector
herein
sought
util
measl
vaccin
vector
activ
antigenspecif
ctl
cytotox
cell
respons
essenti
robust
antivir
antitumor
immun
strategi
induc
ctl
respons
vaccin
includ
peptid
dna
vaccin
target
dc
immun
viral
vector
herein
sought
util
measl
vaccin
vector
activ
antigenspecif
ctl
encod
either
fulllength
antigen
epitop
cassett
variant
within
measl
schwarz
vaccin
backbon
epitop
cassett
variant
encod
either
ctl
epitop
epitop
preced
secret
signal
epitop
string
target
proteasom
degrad
use
cocultur
ctl
cell
treat
measl
vaccin
show
vaccin
activ
cognat
cell
use
virusinfect
tumor
cell
dc
expos
viru
similar
epitop
variant
test
previous
instanc
dna
vaccin
hiv
studi
variant
target
endoplasm
reticulum
especi
proteasom
induc
stronger
immun
respons
studi
measl
vaccin
encod
hepat
b
surfac
antigen
hbsag
singh
et
al
show
uvinactiv
vaccin
elicit
antihbsag
respons
conclud
viral
replic
requir
effect
vaccin
recombin
measl
vaccin
variant
report
replic
effici
show
replic
kinet
similar
unmodifi
vaccin
strain
addit
present
studi
uv
inactiv
abrog
replic
cell
activ
cocultur
mevacsuscept
infect
cell
activ
ctl
line
vaccin
variant
elicit
similar
level
releas
cognat
cell
despit
higher
level
mhcirestrict
epitop
present
epitop
cassett
variant
due
transcript
gradient
within
measl
viru
genom
higher
express
level
antigen
peptid
expect
epitop
cassett
upstream
within
genom
howev
tradeoff
transgen
size
viral
replic
fit
consid
set
mhcirestrict
epitop
present
limit
epitop
cassett
variant
may
benefici
accordingli
cocultur
murin
dc
show
limit
suscept
mevac
epitop
cassett
variant
mediat
pronounc
ctl
activ
compar
mevac
encod
fulllength
antigen
epitop
cassett
design
respect
antigen
process
mechan
genom
posit
epitop
cassett
viral
replic
kinet
may
contribut
observ
differ
activ
level
rennick
et
al
previous
studi
viral
spread
intramuscular
vaccin
macaqu
edmonstonzagreb
measl
vaccin
strain
mvez
encod
gfp
report
found
macrophag
dc
primari
target
cell
mvez
vaccin
show
product
infect
indic
detect
intracellular
viral
protein
present
studi
show
dc
present
virusencod
ctl
epitop
exposur
measl
vaccin
importantli
demonstr
dc
also
prime
epitopespecif
ctl
sinc
tool
studi
ovaspecif
ctl
activ
murin
system
use
murin
dc
experi
assum
human
dc
may
effect
express
mevac
receptor
measl
viru
adapt
human
cell
moreov
measl
vaccin
shown
promot
matur
human
dc
without
compromis
dc
viabil
convent
plasmacytoid
human
dc
shown
crosspres
tumor
antigen
activ
tumorspecif
ctl
exposur
measl
virusinfect
tumor
cell
bolton
et
al
previous
show
measl
vaccin
vector
use
prime
siv
gagspecif
cell
macaqu
could
amplifi
heterolog
adenoviru
boost
taken
togeth
data
indic
measl
vaccin
util
induct
promot
antigenspecif
cell
respons
despit
higher
level
mhcirestrict
epitop
present
releas
mevac
encod
epitop
cassett
variant
encod
fulllength
antigen
offer
possibl
induc
respons
multipl
epitop
one
antigen
includ
epitop
recogn
helper
th
cell
contribut
ctl
respons
altern
distinct
addit
th
ctl
epitop
could
insert
mevac
vector
shown
code
capac
kb
howev
design
multiepitop
vaccin
factor
govern
antigen
domin
cell
precursor
frequenc
rel
epitop
abund
mhc
bind
affin
taken
account
cell
requir
three
signal
full
activ
includ
cell
receptor
engag
mhcepitop
complex
costimul
molecul
surfac
antigenpres
cell
discuss
measl
vaccin
contribut
two
signal
induc
mhc
present
encod
epitop
promot
dc
matur
third
signal
solubl
factor
promot
cell
differenti
requir
shown
releas
context
measl
vaccin
furthermor
transgen
provid
signal
cell
activ
proinflammatori
cytokin
could
incorpor
vector
instanc
measl
vaccin
vector
encod
develop
previous
addit
transgen
promot
dc
function
ctl
induct
prolifer
differenti
prevent
ctl
exhaust
insert
measl
vaccin
vector
previou
exampl
includ
granulocytemacrophag
colonystimul
factor
gmcsf
well
immun
checkpoint
block
antibodi
measl
vaccin
strain
use
oncolyt
virotherapi
shown
induc
antitumor
ctl
respons
via
tumor
vaccin
effect
present
studi
suggest
measl
vaccin
also
design
promot
ctl
respons
specif
tumor
antigen
encod
antigen
immunodomin
epitop
viral
vector
oncolyt
viru
platform
vsv
maraba
viru
use
purpos
though
effect
prime
vector
maraba
virus
encod
tumor
antigen
shown
effici
boost
ctlmediat
antitumor
immun
infect
splenic
follicular
b
cell
thu
maraba
viru
current
appli
heterolog
primeboost
set
replicationdefici
adenovir
vector
previou
work
colleagu
present
data
support
notion
measl
vaccin
use
prime
oncolyt
vaccin
regimen
proofofconcept
studi
carri
experi
establish
vitro
model
system
clearli
vivo
experi
requir
studi
efficaci
well
interplay
compon
immun
system
establish
dose
schedul
regimen
model
commonli
use
test
recombin
measl
vaccin
ifnar
mice
express
measl
vaccin
strain
receptor
defici
type
interferon
receptor
consid
role
type
interferon
antitumor
immun
model
seem
unsuit
studi
oncolyt
vaccin
futur
studi
address
vivo
effect
refin
model
measl
vaccin
tumor
cell
often
acquir
defect
mhci
antigen
process
machineri
therefor
epitop
cassett
variant
facilit
epitop
present
may
prove
benefici
oncolyt
vaccin
set
regard
insert
secret
signal
present
could
repres
one
viabl
strategi
preexist
antimeasl
immun
due
prior
infect
immun
often
consid
obstacl
implement
mevacbas
therapeut
strategi
circumv
prematur
clearanc
develop
includ
chimer
virus
altern
paramyxoviru
platform
howev
preexist
antimeasl
immun
affect
antichikv
immun
respons
human
subject
context
oncolyt
virotherapi
preexist
antivir
immun
may
even
conduc
antitumor
efficaci
taken
togeth
studi
demonstr
measl
vaccin
design
effect
prime
activ
specif
cell
design
principl
adopt
immun
viral
tumor
antigen
develop
cell
vaccin
pathogen
malign
diseas
